Efficacy of New Treatment Modalities in Patients with COVID-19, Qaemshahar Razi Hospital 2020

Background and purpose: Coronavirus Disease-2019) COVID-19) is a respiratory infection which was recognized as a pandemic by the world health organization on march 11, 2020. This study aimed to evaluate new treatment modalities therapy in management of COVID-19. Materials and methods: A descriptive-analytical, retrospective study was performed in patients over 17 years of age with suspected COVID-19 admitted to Qaemshahar Razi Hospital in March and April 2020. The case group included patients treated with methylprednisolone, intravenous immunoglobulin (IVIg), Beta Interferon, Ribavirin, Arbidol, Remdesivir, Favipiravir and Hydroxychloroquine and lopinavir/ritonavir. The control group was selected from hospitalized cases who were treated only with lopinavir/ritonavir and Hydroxychloroquine. This study evaluated the efficacy of these drugs. Data was analyzed in SPSS V18. Results: The mean ages of case group (n=217) and control group were 54.23±16.64 (17-88) years and 53.8±16.23 (19-80) years, respectively. The need for ICU admission and mechanical ventilation were significantly different between the two groups (P<0.05) but no significant difference was seen on mortality rate (P>0.05). Conclusion: Using anti-inflammatory and anti-viral drugs in hospitalized patients seems reasonable until widespread vaccination and development of effective drug.